Mayne Pharma Group (ASX:MYX) said the acquisition of 100% shares in the firm by Cosette Pharmaceuticals is now expected to close in late June to early July, according to a Tuesday Australian bourse filing.
It also signed an agreement with Sol-Gel Technologies to acquire and exclusively license the US rights to TWYNEO, a tretinoin and benzoyl peroxide cream for the treatment of acne vulgaris, and EPSOLAY, for the treatment of inflammatory lesions of rosacea.
The terms of the agreement are $10 million in cash at closing and an additional $6 million in cash six months after closing.
The underlying losses before interest, taxes, depreciation, and amortization for the fiscal third quarter ended March came in at AU$3.4 million, while net sales for the period came in at AU$86.8 million, down 11.3% on the same period in the previous year.
The firm expects to report underlying EBITDA in the range of AU$47 million to AU$51 million for the fiscal year, rising 105% to 123% from the fiscal year 2024.
Price (AUD): $7.05, Change: $+0.060, Percent Change: +0.86%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。